The effect of metformin on depression

Evaluation of Metformin Antidepressant Effect in Women with Polycystic Ovary Syndrome

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251112067975N1

Enrollment

Registered

2025-12-20

Start date

2025-12-11

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: Patients receiving metformin treatment receive 1500 mg from Osveh Company per day for 8 weeks. Intervention 2: Control group: The control group will be treated with

Eligibility

Sex/Gender

Female

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 64 years Definitive diagnosis of polycystic ovary syndrome Absence of acute physical illness

Exclusion criteria

Exclusion criteria: Hypothyroid Hyperprolactinemia Pregnancy Taking metformin or antidepressants in the last 3 months Score 8-13 on the Hamilton Depression Inventory

Design outcomes

Primary

Measure	Time frame
The rate of change in depression severity. Timepoint: Weeks 0, 4, and 8. Method of measurement: Hamilton Depression Rating Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParisa Rajabi

Arak University of Medical Sciences

drparisarajabi@gmail.com+98 86 3313 4057

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026